Immunome, Inc. short interest in 2022
In 2022, Immunome, Inc.'s disclosed short interest ran from 1.82% of shares outstanding on 14 Jan 2022 to 0.43% on 30 Dec 2022, a change of -1.39 percentage points. The year's high was 1.82% on 14 Jan 2022 and its low 0.32% on 15 Aug 2022, averaging 0.70% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.83 days on 31 Oct 2022. Full history: Immunome, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 1.82% (14 Jan 2022)
- End of year
- 0.43% (30 Dec 2022)
- Change
- -1.39 pp
- High
- 1.82% (14 Jan 2022)
- Low
- 0.32% (15 Aug 2022)
- Average
- 0.70%
- Highest days to cover
- 7.83 (31 Oct 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 1.82% | 5.43 | |
| 31 Jan 2022 | 1.32% | 1.94 | |
| 15 Feb 2022 | 1.09% | 3.75 | |
| 28 Feb 2022 | 1.14% | 5.41 | |
| 15 Mar 2022 | 1.09% | 2.25 | |
| 31 Mar 2022 | 1.27% | 1.25 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 0.66% | 1.30 | |
| 29 Apr 2022 | 1.16% | 1.00 | |
| 13 May 2022 | 0.58% | 1.49 | 10-Q filed, results (8-K) |
| 31 May 2022 | 0.69% | 1.28 | |
| 15 Jun 2022 | 0.41% | 1.67 | |
| 30 Jun 2022 | 0.46% | 1.00 | |
| 15 Jul 2022 | 0.43% | 2.24 | |
| 29 Jul 2022 | 0.38% | 2.12 | |
| 15 Aug 2022 | 0.32% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 0.32% | 1.12 | |
| 15 Sep 2022 | 0.35% | 1.55 | |
| 30 Sep 2022 | 0.38% | 2.95 | |
| 14 Oct 2022 | 0.35% | 5.48 | |
| 31 Oct 2022 | 0.38% | 7.83 | |
| 15 Nov 2022 | 0.55% | 4.25 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 0.63% | 3.45 | |
| 15 Dec 2022 | 0.50% | 2.54 | |
| 30 Dec 2022 | 0.43% | 1.61 |
See also: Immunome, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.